EyePoint Pharmaceuticals
Agent50Agent Readiness: 50/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust62Data Trust: 62/100. Above median. Measured by StartupHub.ai. Median 61.Ophthalmology-focused biopharmaceutical company developing sustained-release drug delivery systems for serious eye diseases.
About
EyePoint Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing innovative ophthalmic products for patients with serious eye disorders. Their proprietary Durasert® technology enables sustained intraocular drug delivery, aiming to reduce the frequency of treatments and improve patient outcomes.
Key facts
At-a-glance profile data
- Website
- eyepointpharma.com
- Headquarters
- Watertown, United States
- Founded
- 1987
- Total funding
- $436M (Public Offering)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 14 Oct 2025 | Public Offering | $150M | - |
| 1 Oct 2024 | Public Offering | $161M | - |
| 19 Nov 2021 | Public Offering | $115M | - |
| 28 Mar 2018 | Post IPO | $10M | - |
Tech stack
Detected on eyepointpharma.com, last scanned 5 Jul 2026. Run your own scan
- Hosting
- Google Cloud
- Email provider
- Microsoft 365
Frequently asked
Is EyePoint Pharmaceuticals trustworthy and reputable?
StartupHub's Data Trust & Reputation score for EyePoint Pharmaceuticals is 62 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has EyePoint Pharmaceuticals raised?
EyePoint Pharmaceuticals has raised a total of $436M in funding. The most recent round on record is Public Offering.
What is EyePoint Pharmaceuticals's current status?
EyePoint Pharmaceuticals's current operating status is: Inactive.